Steven C. Katz - Aug 10, 2023 Form 3 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Role
Chief Medical Officer
Signature
/s/ Sean Murphy, Attorney-in-Fact for Steven Katz
Stock symbol
TLSI
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
3
Date filed
8/14/2023, 07:12 PM
Next filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TLSI Common Stock 34.4K Aug 10, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 593 $3.64 Direct F1, F3
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 2.47K $3.64 Direct F1, F4
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 2.47K $1.22 Direct F1, F5
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 2.47K $1.22 Direct F1, F6
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 116K $0.41 Direct F1, F7
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 32.7K $2.43 Direct F1, F8
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 90.2K $2.43 Direct F1, F9
holding TLSI Employee Stock Option (right to buy) Aug 10, 2023 Common Stock 31K $10.30 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).
F2 Includes 16,644 shares issued pursuant to a restricted stock unit award ("RSU"). The RSU vests in four equal annual installments commencing on October 5, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F3 The shares subject to this stock option became fully vested on May 17, 2017.
F4 The shares subject to this stock option became fully vested on January 18, 2019.
F5 The shares subject to this stock option became fully vested on April 18, 2019.
F6 The shares subject to this stock option became fully vested on January 22, 2023.
F7 Twenty-five percent of the shares subject to the option vested on September 21, 2021, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F8 Twenty-five percent of the shares subject to the option vested on November 3, 2022, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F9 1/12th of the shares subject to this stock option vest on May 20, 2025, the first monthly anniversary following the third anniversary of the vesting commencement date with the remainder vesting in 11 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F10 Twenty-five percent of the shares subject to the option vest on May 19, 2024, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.